| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,361,000 |
| Market
Cap: |
722.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15.25 - $15.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aerie Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema. Rhopressa® is a once-daily eye drop designed to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rocklatan® is a once-daily fixed-dose combination of Rhopressa® and latanoprost, a prescribed drug for the treatment of patients with open-angle glaucoma or ocular hypertension. Co. is developing AR-15512, an ophthalmic solution for the treatment of patients with dry eye disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tananbaum James B. |
10% Owner |
– – • |
2016-07-22 |
4 |
B |
$17.50 |
$4,375,000 |
I/I |
250,000 |
1,697,884 |
1.5 |
- |
|
| Mchugh Julie |
Director |
– • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,700 |
1,700 |
|
- |
|
| Goldberg Murray A |
Director |
– • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,700 |
3,400 |
|
- |
|
| Duyk Geoffrey M |
Director |
– • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,700 |
3,400 |
|
- |
|
| Mcgraw Benjamin F III |
Director |
– • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,700 |
3,400 |
|
- |
|
| Du Toit Michael |
Director |
– • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,700 |
1,700 |
|
- |
|
| Croarkin Richard |
Director |
– • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,700 |
1,700 |
|
- |
|
| Cagle Gerald D. |
Director |
– • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,700 |
9,900 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2016-02-25 |
5 |
D |
$16.34 |
$36,847 |
D/D |
(2,255) |
73,018 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2016-02-25 |
5 |
D |
$16.34 |
$11,307 |
D/D |
(692) |
181,983 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2016-02-25 |
5 |
D |
$16.34 |
$15,768 |
D/D |
(965) |
399,132 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2016-02-25 |
5 |
D |
$16.34 |
$21,242 |
D/D |
(1,300) |
27,450 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
400,097 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
11,875 |
28,750 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
178,079 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
25,085 |
75,273 |
|
- |
|
| Cagle Gerald D. |
Director |
– • – |
2015-08-28 |
4 |
B |
$16.60 |
$33,200 |
D/D |
2,000 |
8,200 |
2.39 |
- |
|
| Cagle Gerald D. |
Director |
– • – |
2015-08-12 |
4 |
B |
$15.46 |
$7,729 |
D/D |
500 |
6,200 |
2.39 |
- |
|
| Cagle Gerald D. |
Director |
– • – |
2015-08-10 |
4 |
B |
$16.31 |
$18,766 |
D/D |
1,146 |
5,700 |
2.39 |
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2015-06-15 |
5 |
OE |
$0.01 |
$23 |
D/D |
4,596 |
182,675 |
|
- |
|
| Mehra Anand |
Director |
– • – |
2015-04-15 |
4 |
S |
$33.45 |
$9,843,886 |
I/I |
(294,298) |
469,591 |
|
- |
|
| Mehra Anand |
Director |
– • – |
2015-04-14 |
4 |
S |
$34.08 |
$4,453,880 |
I/I |
(130,702) |
763,889 |
|
- |
|
| Mehra Anand |
Director |
– • – |
2015-04-14 |
4 |
D |
$5.00 |
$110,330 |
I/I |
(22,066) |
894,591 |
|
- |
|
| Mehra Anand |
Director |
– • – |
2015-04-14 |
4 |
OE |
$5.00 |
$750,000 |
I/I |
150,000 |
916,657 |
|
- |
|
| Gryska David W |
Director |
– • – |
2015-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,700 |
1,700 |
|
- |
|
333 Records found
|
|
Page 12 of 14 |
|
|
